Twentyeight-Seven Therapeutics
https://www.twentyeight-seven.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Twentyeight-Seven Therapeutics
Biohaven Makes Bet On Brain-Penetrant TYK2/JAK1 Inhibitor For Neurological Diseases
The company, which has struggled in the clinic following a deal where Pfizer bought its migraine portfolio, is licensing the dual inhibitor drug from a Chinese firm for up to $970m.
Deal Watch: OrsoBio Reveals Its Metabolic Health Focus With Four Licensing Pacts
California biotech also notes prior licensing deal with Gilead for mitochondrial candidate. Twentyeight-Seven acquires RNA-splicing cancer candidate from Basilea.
Finance Watch: Q1 Numbers Suggest A Brisk VC Deal Pace For Cell And Gene Therapies In 2019
An Alliance for Regenerative Medicine (ARM) report shows big Q1 numbers for venture capital and partnership deals. Also, mid-May VC deals surge globally across therapeutic areas, Biogen pushes back against a bargain-hunting investor and recent public company financings.
Start-Up Quarterly Statistics: Q3 Financings Slump Despite Large Gossamer Series B, Big Rubius IPO
Third quarter biopharma start-up financing activity decreased from the record-breaking Q2. A review of biopharma start-up dealmaking and financing activity from July through September 2018, based on data from Strategic Transactions.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Drug Discovery Technologies
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- 28-7 Therapeutics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice